Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OPGN: delisted from the Nasdaq to the OTC. As usual, people who knew beforehand drove the PPS to $2.80, then after the announcement the stock dropped to $1.80. Isn't that spessssssshial.....the buggers.
Please ; SOMEbody ?........Just what WAS "the 2021 OTC rule change" ?
OPGN and Lazar plays are lame.
OTC stocks aren’t fun when the current plays are low float Nasdaq stocks.
But… great calls on GCTS and IBIO.
You're absolutely right. However, if you examine closely, you'll notice the identical process being employed in stocks under $1 as in the OTC. Have you observed the surge of "NO NEWS STOCKS" causing a 65%-100%+ increase?
Trade them and if you have the acoount and funds...SHORT THEM. We are all here to make money. However some only know one way. The 2021 rule change was implemented to bring that OTC money to the NASDAQ.
Absolutely RS has been very profitable for traders in Nasdaq.
OTC market has been crap since those fun times in early 2021.
Have fun here. I am not interested in a Lazar/OTC/RS play.
You might make good change here.
Just make sure you have a quick itchy finger to protect profits.
As a trader, you're aware that this is the typical outcome for 90% of penny stocks and OTC stocks. The Nasdaq has been experiencing a profitable trend with reverse split plays for the past few months. "WE TRADE". Currently, I'm holding at my average of $0.55, but when I saw the opportunity to short, I seized it. If you believe they're worthless, short them. Play the market from both angles... $$
Very familiar with him and his tendency to RS most of his plays.
I see only 1 true success.
Most of the others have moved back to below a penny.
You've yet to witness a favorable result? Where have you been? It seems you're not familiar with David Lazar. If you never" traded" OTC stocks then I can understand your opinion.
https://investorshub.advfn.com/David-Lazars-OTC-SPACs-CUSTODIAN-Plays-35757
Lessee… 3M shares of preferred for a buck a piece that convert into common stock at a 24-1 ratio… that’s like 4 cents a share….
He gets stock at 4 cents a share…… and folks think that’s a good thing, so good they’re paying nearly a buck a share today?
Wash trading robots are on, don’t get trapped. This won’t last. O/S turned over a couple times already on a stock that was trading 100-200k on good days.
Lazar loves to RS his plays.
I have never seen a positive outcome on any of his plays.
Maybe this will be different.
I wouldn’t bet the bank and would takes profits.
JMO.
He worked wonders on MINM... Gotta believe that will propel this higher
Lazar taking a stake here... o/s looks to be ballooning 10m to 80m tho.
Yes chased 4 yesterday
Dauum you didn’t get to sell or did you buy high
Done I'm trapped 4 forever
Can it do a wash rinse repeat or is it done
Nothing like selling 1000 shares of preferred stock convertible into common stock at 49 cents per share and having the PPS wash traded up to $2.20…
The trap has been sprung.
Which short is underwater. Wooo. Rally!
Same admins wont do anything
I continue to report you with your spam
Worked yesterday
Hopefully throw you in ihub jail next
Its only up 991%
Moving up real fast.
An 8k was released AH but ppl have a tough time reading through them
Can't figure out why on this one either.
excellent,lmao,enjoy all that marine biology,drink plenty of liquids
power hour soon,those who wanted out,are out,macd oversold>green just crossed to upside,bulls normally follow soon
mid-day vol. surge,all accululation,walkdown was accumulation also,hording going on,its like a buyback!!
did u buy and cause the explosion,its running now
OPGN: Hey, THANKS for that, Dude!!
cancelled the dilutive funding,buyout makes sense,if going bk they would still do bad funding then bk
consolidated well,bounced off 200ma(10min),doji dragonfly yesterday>excellent candle sign of reversal coming(dont know if your still watching this one friend,thought you might want to know with listed medical devise's hot lately,and the other one running like mad with no short fee,might now be ready yet but jic)
270k shares short,49% fee,time to cover bitches
eps qq up 63%,demand growing/supply was @.385,thru that as i typed,wow!!!
upticks on few hundred shares,so far letting it go today,all natural accumulation
watch for big institutional slaps 20k+,under the radar with low vol atm,top of my scanner now
relative buying vol. up 1576% today,institutional starting ?,insiders know what is coming,8mms stacked wanting shares on this low float
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2720
|
Created
|
07/29/15
|
Type
|
Free
|
Moderators |
Vexing problems oftimes lead to creative solutions. OpGen's robust ingenuity is a case in point.
Problem: "Antibiotic resistance is a global threat. There is no system in place to track antibiotic resistance globally. Without urgent action, many modern medicines could become obsolete, turning even common infections into deadly threats." -U.S. Center for Disease Control
Enter OpGen, Inc. Press Releases
OpGen, Inc. (Gaithersburg, MD, USA) (Nasdaq OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to guide clinicians with rapid and actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDRO). Subsidiaries include Curetis GmbH and
Ares Genetics GmbH*. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI. Learn more
OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, PNA FISH, Quick Fish, Acuitas® Lighthouse, and the ARES Technology Platform. The Ares Technology Platform includes ARESdb (db=database) that uses NGS (next generation sequencing) technology and AI-powered bioinformatics solutions to predict antibiotic response (resistance). Artificial intelligence based DNA testing revolutionizes infectious disease diagnostics and therapeutics.* Patient outcomes improved; costs reduced. Learn more
"Time is of the essence in cases of severe infections, not infrequently a question of life or death, and knowing what not to prescribe is as important as knowing what to prescribe."
OpGen Corporate Overview 06-Oct-2020 (Recommended viewing)
*02Oct2020 OpGen's wholly owned Ares Genetics GmbH* (Vienna) won the Austria State Prize for innovation with their Project "ARESupa- Molecular Antibiotic Resistance Diagnostics using Artificial Intelligence - With a (Ares Genetics) universal pathogen test, antibiotic resistance from germs can be predicted quickly and accurately."
OpGen subsidiary Ares Genetics, which combines Next Generation Sequencing (NGS) with ARESdb, is the world‘s most comprehensive database on the genetics of antibiotic resistance. ARESdb is also the world’s largest database of genetic antibiotic resistance markers and predictive AMR panels. ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally. ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with ~98% accuracy. ARESdb covers 30 years of emerging antibiotic resistance to accurately detect AMR and combines deep whole-genome sequencing data with antibiotic resistance profiles continuously expanded. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI.
Fast & Simple Syndromic Testing for Severe Infections -- Improving Patient Outcomes
Detects pathogens rapidly, including associated antibiotic resistance genes
Antibiotic resistant microorganisms are a global health threat (Per CDC, WHO, US GAO)
Our UNYVERO A50 IS FDA APPROVED UNYVERO FLYER (Recommended viewing)
With the Unyvero A50 Solution, OPGen's wholly owned subsidiary Curetis has developed a molecular diagnostics system for reliable and extremely rapid diagnosis of severe infectious diseases in under 5 hours versus up to 96 hours using current methods. The system uses powerful multiplex PCR technology and syndromic testing to detect a wide variety of microorganisms, antibiotic resistance markers, or toxins.
Unyvero A50 Applications for Major Infectious Disease
HPN- Hospitalized Pneumonia
HPN Solution
BCU — Blood Culture
Analyzes the DNA of 103 pathogens & resistance genes from a
positive blood culture for fast diagnostics of blood stream infections.
BCU Solution
IAI — Intra-Abdominal Infection
IAI Solution
UTI — Urinary Tract Infection
Unyvero A50 System
Unyvero A50 Cartridge
Applications
Unyvero A30 RQ in development
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |